Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22737182 | 0.90 | CYP1A2 (0.33) | CYP1A2HRH3L3MBTL3L3MBTL1 | |
| SCHEMBL26748933 | 0.88 | HRH3 (0.34) | CYP1A2HRH3L3MBTL3L3MBTL1 | |
| SCHEMBL26752530 | 0.83 | HRH3 (0.33) | HRH3 | |
| SCHEMBL24185486 | 0.83 | HRH3 (0.33) | CYP1A2HRH3L3MBTL3L3MBTL1 | |
| SCHEMBL25856032 | 0.81 | L3MBTL3 (0.33) | CYP1A2HRH3L3MBTL3L3MBTL1 | |
| SCHEMBL25508591 | 0.81 | HRH3 (0.31) | HRH3L3MBTL3L3MBTL1 | |
| SCHEMBL24185456 | 0.80 | HRH3 (0.32) | HRH3L3MBTL3L3MBTL1 | |
| SCHEMBL24185483 | 0.80 | TSHR (0.33) | CYP1A2HRH3 | |
| SCHEMBL24185940 | 0.80 | HRH3 (0.33) | HRH3L3MBTL3L3MBTL1 | |
| SCHEMBL25513290 | 0.79 | CYP1A2 (0.30) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219906-A1 | MACROCYCLIC-2-AMINO-3-FLUORO-BUT-3-ENAMIDES AS INHIBITORS OF MCL-1 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219906-A1 | MACROCYCLIC-2-AMINO-3-FLUORO-BUT-3-ENAMIDES AS INHIBITORS OF MCL-1 | MCL1, BCL2L1, BCL2A1 | CYP1A2 3092/4885HRH3 3330/4885L3MBTL3 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.